Halozyme Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Halozyme Therapeutics Inc in the third quarter 2026?
Halozyme Therapeutics Inc achieved a return on average equity (ROE) of 544.26 % in its third quarter 2026, this is above HALO's average return on equity of -59.26%.
Halozyme Therapeutics Inc shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $89 million

ROE has advanced compared to 180.63% in the second quarter 2026, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry only one company had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 66, from total ROE ranking in the second quarter 2026 at 72.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	-	-56.86 %	-54.46 %	-86.58 %	-
Y / Y Net Income Change	40.99 %	39.21 %	27.06 %	-	27.89 %
Net Income (TTM) in Millions	485	414	349	317	595
Return On Equity (TTM)	544.26 %	180.63 %	126.27 %	92.67 %	141.55 %
HALO's Total Ranking	# 66	# 72	# 21	# 40	#
Equity (TTM) in Millions	-55	144	220	49	504
Seq. Equity Change	-	-34.65 %	349.94 %	-90.31 %	51.44 %
Seq. Net Income Change	7.45 %	53.23 %	-	-	6.09 %

Back to HALO Management Effectiveness >> HALO's 5 Years Annual ROE >> Compare HALO ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 2
Sector	# 9
Overall	# 66

Return On Equity Statistics
High	Average	Low
263.91 %	-59.26 %	-1725.85 %
(Sep 30 2021)		(Dec 31 2013)

HALO Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	49	364	84	170	197
Y / Y Equity Change	-86.58 %	334.11 %	-50.64 %	-13.79 %	30.39 %
Net Income in Millions	317	444	282	202	403
Y / Y Net Income Change	-28.64 %	57.71 %	39.31 %	-49.81 %	211.97 %
Return On Equity	649.18 %	122.06 %	336 %	119.04 %	204.47 %

Back to HALO Management Effectiveness >> HALO's 5 Years Annual ROE >> Compare HALO ROE to its Competitors

Annual Roe Comment

Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 649.18 % compared to the prior year.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
HALO's' Return on Equity at Yahoo Finance
HALO's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for HALO's Competitors
Subscribers only: Roe for Halozyme Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for HALO's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Halozyme Therapeutics Inc	544.26 %
Alnylam Pharmaceuticals Inc	159.72 %
Amneal Pharmaceuticals Inc	157.05 %
Alector Inc	112.21 %

Date modified: 2026-11-09T06:45:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.